Frank RG, et al. - Researchers characterized the differences between 2009 and 2016 in the amount of Medicaid-covered naloxone used, as well as between states that expanded their Medicaid programs and states that did not. Starting in 2014, a quasi-experimental study according to states’ decision to expand their Medicaid program to all adults with incomes between 100% and 138% of the federal poverty line was performed. Thirty-one states had expanded while 14 states that had not, as of 2018. Medicaid-covered naloxone prescriptions were comparable across the states before the expansion, but afterwards states that expanded saw a nearly 10-fold increase in naloxone prescriptions vs the years before expansion. Approximately 25% of naloxone sales were attributed to Medicaid. From 2009 to 2016, they observed 8.3% of the growth in naloxone units was attributable to Medicaid expansion.